Upstream Bioprocessing Market Scope And Analysis

Upstream Bioprocessing Market Report Scope

Industry Developments and Future Opportunities: 

Different initiatives by prominent players in the global upstream bioprocessing market are listed below:

1. In December 2023, Merck acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. The purchase boosts Merck's upstream therapeutic protein portfolio, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
2. In October 2023, Getinge AB acquired High Purity New England, Inc. for US$ 120 million. By the end of 2024, the company will fully integrate High Purity New England, Inc. The acquisition has helped Getinge AB acquire a comprehensive range of proprietary and distributed products from drug discovery, upstream and downstream processing, and fill-and-finish.
3. In January 2023, Sartorius collaborated with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
4. In February 2022, Thermo Fisher Scientific In announced an expansion for its Bioprocessing. The company has invested US$40 million to construct and maintain a manufacturing plant for single-use technologies in Millersburg, Pennsylvania. The expansion was part of a multi-year, US$ 650 million investment to improve the company's capacity to produce bioprocessing in a flexible, scalable, and dependable manner.
5. In March 2021, Thermo Fisher Scientific Inc launched HyPerforma DynaDrive S.U.B. in different volumes, 3,000 L and 5,000 L models. Thermo Fisher Scientific's largest commercially accessible S.U.B., the first-of-its-size 5,000 L S.U.B., allows biopharmaceutical businesses to incorporate single-use technologies into large-scale bioprocesses, such as cGMP manufacture at very high cell density and perfusion cell culture.

Competitive Landscape and Key Companies:

Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc are among the prominent players operating in the upstream bioprocessing market. These companies focus on the development and adoption of new technologies, advancements in existing products, and expansion of their geographic presence to meet the growing consumer demand worldwide.